Time New York: Thu 19 Oct 12:34 pm  |  Save 15% on H&R Block Online

  
caticonslite_bm_alt

Clovis (CLVS) Submits sNDA for Ovarian Cancer Drug Rubraca

Zacks

Clovis Oncology CLVS announced the submission of a supplemental New Drug Application (sNDA) for Rubraca (rucaparib) to the FDA. The sNDA is looking to expand Rubraca’s label as a maintenance treatment for patients with platinum-sensitive recurrent ovarian cancer.

We remind investors that Rubraca, a PARP inhibitor, had received accelerated approval as monotherapy in advanced ovarian cancer patients with deleterious BRCA mutation, treated with two or more chemotherapies in December 2016. Clovis is conducting confirmatory studies to convert this approval to a full approval.

Clovis’ stock was up 1.8% in after-market trading following the news. In fact, shares of the company are up almost 88% so far this year, significantly outperforming the industry’s gain of 13.9% in that period.


The sNDA was submitted based on promising data from the confirmatory phase III study – ARIEL 3 – announced in June this year. Rubraca demonstrated a meaningful impact in delaying disease recurrence in advanced ovarian cancer patients who are either BRCA mutant or HRD positive.

The company is committed to expand the label of Rubraca for a broader population of women with ovarian cancer, which is evident from the fact that it filed the sNDA within four months of its top-line data announcement. Moreover, Clovis offered its common stock in June to raise an aggregate of $300 million in net proceeds, which it plans to use partly for promotional and marketing expense associated with Rubraca.

Meanwhile, Rubraca as a monotherapy is also under review in the EU for treating advanced ovarian cancer. Clovis is planning to file a marketing authorization application in early 2018 for maintenance treatment following the potential approval as monotherapy.

A potential approval in the EU and label expansion in the United States is expected to boost the potential of the drug. It has generated sales of nearly $15 million in the first half of 2017, following its approval in December last year. Also, during this period, more than 1000 patients started using the therapy.

However, Clovis’ Rubraca will face competition from other PARP inhibitors, which include Tesaro, Inc.’s TSRO Zejula and AstraZeneca plc’s AZN Lynparza.

Meanwhile, the second phase III confirmatory study, ARIEL4, is evaluating Rubraca versus chemotherapy in patients who have failed two prior lines of therapy. Clovis is also looking to expand Rubraca’s label into additional indications like prostrate, breast and pancreatic cancers, among others, either as monotherapy or in combination with other agents.

Several clinical studies were initiated in early 2017, including TRITON2 and TRITON3 in prostate cancer and a Tecentriq-Rubraca combination study in gynecologic cancers, which is sponsored by Roche Holding AG RHHBY.

Clovis carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Today's Stocks from Zacks' Hottest Strategies

It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 – Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.

And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 – Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Zacks Investment Research
<-- You can share this post with your network,
or give us your opinion and leave a comment.
Be sure to check our RSS feeds for updates.